您当前所在的位置:首页 > 产品中心 > 产品详细信息
23155-02-4 分子结构
点击图片或这里关闭

[(2R,3S)-3-methyloxiran-2-yl]phosphonic acid

ChemBase编号:707
分子式:C3H7O4P
平均质量:138.059041
单一同位素质量:138.00819533
SMILES和InChIs

SMILES:
P(=O)(O)(O)[C@H]1O[C@H]1C
Canonical SMILES:
C[C@@H]1O[C@@H]1P(=O)(O)O
InChI:
InChI=1S/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/t2-,3+/m0/s1
InChIKey:
YMDXZJFXQJVXBF-STHAYSLISA-N

引用这个纪录

CBID:707 http://www.chembase.cn/molecule-707.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
[(2R,3S)-3-methyloxiran-2-yl]phosphonic acid
IUPAC传统名
fosfomycin
商标名
Monurol
Veramina
别名
Fosfomycin disodium salt
Fosfomycin sodium
Fosfocina
Fosfonomycin
Phosphomycin
phosphomycin disodium salt
Phosphonomycin
Fosfomycin
CAS号
23155-02-4
PubChem SID
160964170
46506665
PubChem CID
446987

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID
DrugBank DB00828 external link
PubChem 446987 external link
数据来源 数据ID 价格

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 1.2504967  质子受体
质子供体 LogD (pH = 5.5) -3.0407646 
LogD (pH = 7.4) -3.1824315  Log P -0.7377749 
摩尔折射率 25.8737 cm3 极化性 10.712277 Å3
极化表面积 70.06 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P -0.86  LOG S -0.47 
溶解度 4.69e+01 g/l 

分子性质

分子性质

理化性质 生物活性(PubChem)
溶解度
50 mg/mL (Sodium salt) expand 查看数据来源
疏水性(logP)
-1.6 expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank
DrugBank -  DB00828 external link
Item Information
Drug Groups approved
Description An antibiotic produced by Streptomyces fradiae. [PubChem]
Indication For the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis.
Pharmacology Fosfomycin is a broad spectrum antibiotic that concentrates in kidney and bladder and is used to treat uncomplicated urinary tract infections. Fosfomycin also reduces nephrotoxicity and ototoxicity of platinum-containing anti-tumor agents.
Toxicity LD50>5 g/kg (rats). Side effects may include diarrhea
Affected Organisms
Enteric bacteria and other eubacteria
Biotransformation No transformation, excreted unchanged
Absorption Fosfomycin tromethamine is rapidly absorbed following oral administration and converted to fosfomycin. Oral bioavailability under fasting conditions is 37%. When given with food, oral bioavailability is reduced to 30%
Half Life 5.7 (± 2.8) hours. The elimination half-life is 40 hours in anuric patients undergoing hemodialysis.
Protein Binding 0% (not bound to plasma proteins)
Elimination Fosfomycin is excreted unchanged in both urine and feces.
Distribution * 136.1 ±44.1 L
Clearance * 16.9 +/- 3.5 L/hr
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
    暂无数据
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle